Cargando…
Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis
BACKGROUND: The association of CD133 overexpression with clinicopathological significance and prognosis in patients with breast cancer remains controversial. We thus performed a meta-analysis to evaluate the role of CD133 expression in the development and prognosis of breast cancer. METHODS: The dat...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317305/ https://www.ncbi.nlm.nih.gov/pubmed/28243121 http://dx.doi.org/10.2147/OTT.S124733 |
_version_ | 1782508979668123648 |
---|---|
author | Li, Zhan Yin, Songcheng Zhang, Lei Liu, Weiguang Chen, Bo Xing, Hua |
author_facet | Li, Zhan Yin, Songcheng Zhang, Lei Liu, Weiguang Chen, Bo Xing, Hua |
author_sort | Li, Zhan |
collection | PubMed |
description | BACKGROUND: The association of CD133 overexpression with clinicopathological significance and prognosis in patients with breast cancer remains controversial. We thus performed a meta-analysis to evaluate the role of CD133 expression in the development and prognosis of breast cancer. METHODS: The databases PubMed, Embase, and Cochrane Library (updated to August 1, 2016) were searched. Pooled odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (95% CI) were used to evaluate the impact of CD133 expression on clinicopathological features, overall survival, and disease-free survival. RESULTS: A total of 1,734 patients from 13 studies were subject to final analysis. The results showed a significant association between overexpression of CD133 and estrogen receptor status (OR 0.35, 95% CI 0.18–0.70), progesterone receptor status (OR 0.56, 95% CI 0.43–0.74), human epidermal growth factor-2 status (OR 1.81, 95% CI 1.33–2.45), lymph node metastasis (OR 1.98, 95% CI 1.34–2.92), and tumor histological grade (OR 1.79, 95% CI 1.26–2.54) in breast cancer. However, no significant correlation was found between upregulation of CD133 expression and onset age (OR 1.03, 95% CI 0.70–1.53) or tumor size (OR 1.29, 95% CI 0.80–2.09). Moreover, CD133-positive breast cancer patients had a higher risk of mortality (HR 1.91, 95% CI 1.21–3.03) and disease progression (HR 2.70, 95% CI 1.05–6.95). CONCLUSION: This meta-analysis suggested that CD133 might be a predictor of clinical outcomes as well as prognosis and could be a potentially new gene therapy target for breast cancer patients. |
format | Online Article Text |
id | pubmed-5317305 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-53173052017-02-27 Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis Li, Zhan Yin, Songcheng Zhang, Lei Liu, Weiguang Chen, Bo Xing, Hua Onco Targets Ther Original Research BACKGROUND: The association of CD133 overexpression with clinicopathological significance and prognosis in patients with breast cancer remains controversial. We thus performed a meta-analysis to evaluate the role of CD133 expression in the development and prognosis of breast cancer. METHODS: The databases PubMed, Embase, and Cochrane Library (updated to August 1, 2016) were searched. Pooled odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (95% CI) were used to evaluate the impact of CD133 expression on clinicopathological features, overall survival, and disease-free survival. RESULTS: A total of 1,734 patients from 13 studies were subject to final analysis. The results showed a significant association between overexpression of CD133 and estrogen receptor status (OR 0.35, 95% CI 0.18–0.70), progesterone receptor status (OR 0.56, 95% CI 0.43–0.74), human epidermal growth factor-2 status (OR 1.81, 95% CI 1.33–2.45), lymph node metastasis (OR 1.98, 95% CI 1.34–2.92), and tumor histological grade (OR 1.79, 95% CI 1.26–2.54) in breast cancer. However, no significant correlation was found between upregulation of CD133 expression and onset age (OR 1.03, 95% CI 0.70–1.53) or tumor size (OR 1.29, 95% CI 0.80–2.09). Moreover, CD133-positive breast cancer patients had a higher risk of mortality (HR 1.91, 95% CI 1.21–3.03) and disease progression (HR 2.70, 95% CI 1.05–6.95). CONCLUSION: This meta-analysis suggested that CD133 might be a predictor of clinical outcomes as well as prognosis and could be a potentially new gene therapy target for breast cancer patients. Dove Medical Press 2017-02-14 /pmc/articles/PMC5317305/ /pubmed/28243121 http://dx.doi.org/10.2147/OTT.S124733 Text en © 2017 Li et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Li, Zhan Yin, Songcheng Zhang, Lei Liu, Weiguang Chen, Bo Xing, Hua Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis |
title | Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis |
title_full | Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis |
title_fullStr | Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis |
title_full_unstemmed | Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis |
title_short | Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis |
title_sort | clinicopathological characteristics and prognostic value of cancer stem cell marker cd133 in breast cancer: a meta-analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5317305/ https://www.ncbi.nlm.nih.gov/pubmed/28243121 http://dx.doi.org/10.2147/OTT.S124733 |
work_keys_str_mv | AT lizhan clinicopathologicalcharacteristicsandprognosticvalueofcancerstemcellmarkercd133inbreastcancerametaanalysis AT yinsongcheng clinicopathologicalcharacteristicsandprognosticvalueofcancerstemcellmarkercd133inbreastcancerametaanalysis AT zhanglei clinicopathologicalcharacteristicsandprognosticvalueofcancerstemcellmarkercd133inbreastcancerametaanalysis AT liuweiguang clinicopathologicalcharacteristicsandprognosticvalueofcancerstemcellmarkercd133inbreastcancerametaanalysis AT chenbo clinicopathologicalcharacteristicsandprognosticvalueofcancerstemcellmarkercd133inbreastcancerametaanalysis AT xinghua clinicopathologicalcharacteristicsandprognosticvalueofcancerstemcellmarkercd133inbreastcancerametaanalysis |